PuraCap Pharmaceutical of South Plainfield, NJ, in the US, has acquired Blu Pharmaceutical and Blu Caribe creating PuraCap International, a joint venture between PuraCap and Dangdai International Group of China, for an undisclosed sum.
The acquisition will expand PuraCap's manufacturing expertise beyond soft gelatin capsules to include oral tablet and capsule dosage forms for both the US and global markets.
'This acquisition is a major step in the growth of our capability in the manufacturing of oral solid dosage forms in the US, which complements our state-of-the-art soft gelatin capsule manufacturing facility in Wuhan, China,' said PuraCap Pharmaceutical CEO Dahai Guo.
The acquisition includes a state-of-the-art 145,000ft2 (13,500m2) FDA approved, cGMP compliant manufacturing facility in Dorado, Puerto Rico, as well as an 185,000ft2 (17,187m2) warehouse and distribution centre in Franklin, Kentucky, US.
'This acquisition brings us further infrastructure and sales channels, not only in the retail generic drug business, but also in the US government purchasing tender business channel to help meet the growing demand for generic prescription products,' said Sean Weeks, President of PuraCap International.
